Passage Bio Net Income
| PASG Stock | USD 8.81 0.08 0.92% |
As of the 17th of February 2026, Passage Bio holds the Semi Deviation of 6.68, coefficient of variation of 1133.32, and Risk Adjusted Performance of 0.0802. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Passage Bio, as well as the relationship between them. Please check Passage Bio information ratio, value at risk, as well as the relationship between the Value At Risk and expected short fall to decide if Passage Bio is priced some-what accurately, providing market reflects its current price of 8.81 per share. Given that Passage Bio has jensen alpha of 0.4631, we recommend you to check out Passage Bio's recent market performance to make sure the company can sustain itself at a future point.
Passage Bio's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Passage Bio's valuation are provided below:There are over one hundred nineteen available trending fundamental ratios for Passage Bio, which can be analyzed over time and compared to other ratios. Active traders should verify all of Passage Bio recent fundamental drivers against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -58.3 M | -61.2 M | |
| Net Loss | -122.5 M | -128.6 M | |
| Net Loss | -58.3 M | -61.2 M | |
| Net Loss | (24.66) | (25.89) |
Passage | Net Income | Build AI portfolio with Passage Stock |
The Net Income trend for Passage Bio offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Passage Bio is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Passage Bio's Net Income Growth Pattern
Below is the plot of the Net Income of Passage Bio over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Passage Bio financial statement analysis. It represents the amount of money remaining after all of Passage Bio operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Passage Bio's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Passage Bio's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (64.77 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Passage Net Income Regression Statistics
| Arithmetic Mean | (51,801,830) | |
| Coefficient Of Variation | (102.58) | |
| Mean Deviation | 42,053,447 | |
| Median | (12,770,000) | |
| Standard Deviation | 53,139,572 | |
| Sample Variance | 2823.8T | |
| Range | 172.6M | |
| R-Value | (0.63) | |
| Mean Square Error | 1814.2T | |
| R-Squared | 0.40 | |
| Significance | 0.01 | |
| Slope | (6,636,320) | |
| Total Sum of Squares | 45181T |
Passage Net Income History
Other Fundumenentals of Passage Bio
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Passage Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Passage Bio is extremely important. It helps to project a fair market value of Passage Stock properly, considering its historical fundamentals such as Net Income. Since Passage Bio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Passage Bio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Passage Bio's interrelated accounts and indicators.
Click cells to compare fundamentals
Can Biotechnology industry sustain growth momentum? Does Passage have expansion opportunities? Factors like these will boost the valuation of Passage Bio. Anticipated expansion of Passage directly elevates investor willingness to pay premium valuations. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Passage Bio demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Investors evaluate Passage Bio using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Passage Bio's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. External factors like market trends, sector rotation, and investor psychology can cause Passage Bio's market price to deviate significantly from intrinsic value.
It's important to distinguish between Passage Bio's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Passage Bio should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Passage Bio's market price signifies the transaction level at which participants voluntarily complete trades.
Passage Bio 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Passage Bio's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Passage Bio.
| 11/19/2025 |
| 02/17/2026 |
If you would invest 0.00 in Passage Bio on November 19, 2025 and sell it all today you would earn a total of 0.00 from holding Passage Bio or generate 0.0% return on investment in Passage Bio over 90 days. Passage Bio is related to or competes with NuCana PLC, MetaVia, Lisata Therapeutics, Allarity Therapeutics, CytoMed Therapeutics, Enlivex Therapeutics, and Cingulate. Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases More
Passage Bio Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Passage Bio's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Passage Bio upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 7.29 | |||
| Information Ratio | 0.08 | |||
| Maximum Drawdown | 58.13 | |||
| Value At Risk | (9.87) | |||
| Potential Upside | 14.59 |
Passage Bio Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Passage Bio's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Passage Bio's standard deviation. In reality, there are many statistical measures that can use Passage Bio historical prices to predict the future Passage Bio's volatility.| Risk Adjusted Performance | 0.0802 | |||
| Jensen Alpha | 0.4631 | |||
| Total Risk Alpha | 0.1083 | |||
| Sortino Ratio | 0.093 | |||
| Treynor Ratio | 0.161 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Passage Bio's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Passage Bio February 17, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0802 | |||
| Market Risk Adjusted Performance | 0.171 | |||
| Mean Deviation | 5.94 | |||
| Semi Deviation | 6.68 | |||
| Downside Deviation | 7.29 | |||
| Coefficient Of Variation | 1133.32 | |||
| Standard Deviation | 8.48 | |||
| Variance | 71.84 | |||
| Information Ratio | 0.08 | |||
| Jensen Alpha | 0.4631 | |||
| Total Risk Alpha | 0.1083 | |||
| Sortino Ratio | 0.093 | |||
| Treynor Ratio | 0.161 | |||
| Maximum Drawdown | 58.13 | |||
| Value At Risk | (9.87) | |||
| Potential Upside | 14.59 | |||
| Downside Variance | 53.17 | |||
| Semi Variance | 44.58 | |||
| Expected Short fall | (6.29) | |||
| Skewness | 1.25 | |||
| Kurtosis | 5.1 |
Passage Bio Backtested Returns
Passage Bio appears to be slightly risky, given 3 months investment horizon. Passage Bio maintains Sharpe Ratio (i.e., Efficiency) of 0.0606, which implies the firm had a 0.0606 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Passage Bio, which you can use to evaluate the volatility of the company. Please evaluate Passage Bio's Coefficient Of Variation of 1133.32, semi deviation of 6.68, and Risk Adjusted Performance of 0.0802 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Passage Bio holds a performance score of 4. The company holds a Beta of 4.58, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Passage Bio will likely underperform. Please check Passage Bio's expected short fall, and the relationship between the value at risk and daily balance of power , to make a quick decision on whether Passage Bio's historical price patterns will revert.
Auto-correlation | -0.79 |
Almost perfect reverse predictability
Passage Bio has almost perfect reverse predictability. Overlapping area represents the amount of predictability between Passage Bio time series from 19th of November 2025 to 3rd of January 2026 and 3rd of January 2026 to 17th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Passage Bio price movement. The serial correlation of -0.79 indicates that around 79.0% of current Passage Bio price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.79 | |
| Spearman Rank Test | -0.84 | |
| Residual Average | 0.0 | |
| Price Variance | 10.67 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Passage Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Passage Bio reported net income of (64.77 Million). This is 118.98% lower than that of the Biotechnology sector and 192.46% lower than that of the Health Care industry. The net income for all United States stocks is 111.34% higher than that of the company.
Passage Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Passage Bio's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Passage Bio could also be used in its relative valuation, which is a method of valuing Passage Bio by comparing valuation metrics of similar companies.Passage Bio is currently under evaluation in net income category among its peers.
Passage Bio ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Passage Bio's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Passage Bio's managers, analysts, and investors.Environmental | Governance | Social |
Passage Bio Institutional Holders
Institutional Holdings refers to the ownership stake in Passage Bio that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Passage Bio's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Passage Bio's value.| Shares | State Street Corp | 2025-03-31 | 156.8 K | Rbf Llc | 2025-03-31 | 142.8 K | Millennium Management Llc | 2025-03-31 | 136.2 K | Northern Trust Corp | 2025-03-31 | 112 K | Simplex Trading, Llc | 2025-03-31 | 82.3 K | Two Sigma Investments Llc | 2025-03-31 | 47 K | Xtx Topco Ltd | 2025-03-31 | 45.4 K | Ubs Group Ag | 2025-03-31 | 14.5 K | Mariner Wealth Advisors Llc | 2025-03-31 | 11.9 K | Orbimed Advisors, Llc | 2025-03-31 | 7 M | Vestal Point Capital Lp | 2025-03-31 | 6.1 M |
Passage Fundamentals
| Return On Equity | -0.87 | ||||
| Return On Asset | -0.32 | ||||
| Current Valuation | 858.36 K | ||||
| Shares Outstanding | 3.18 M | ||||
| Shares Owned By Insiders | 0.21 % | ||||
| Shares Owned By Institutions | 51.12 % | ||||
| Number Of Shares Shorted | 11.22 K | ||||
| Price To Book | 0.94 X | ||||
| EBITDA | (62.09 M) | ||||
| Net Income | (64.77 M) | ||||
| Cash And Equivalents | 239.25 M | ||||
| Cash Per Share | 4.39 X | ||||
| Total Debt | 25.48 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 9.23 X | ||||
| Book Value Per Share | 9.79 X | ||||
| Cash Flow From Operations | (47.96 M) | ||||
| Short Ratio | 0.13 X | ||||
| Earnings Per Share | (14.62) X | ||||
| Target Price | 39.6 | ||||
| Number Of Employees | 60 | ||||
| Beta | 1.73 | ||||
| Market Capitalization | 28 M | ||||
| Total Asset | 102.41 M | ||||
| Retained Earnings | (659.24 M) | ||||
| Working Capital | 59.45 M | ||||
| Current Asset | 144.91 M | ||||
| Current Liabilities | 3.09 M | ||||
| Net Asset | 102.41 M |
About Passage Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Passage Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Passage Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Passage Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out For more detail on how to invest in Passage Stock please use our How to Invest in Passage Bio guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Can Biotechnology industry sustain growth momentum? Does Passage have expansion opportunities? Factors like these will boost the valuation of Passage Bio. Anticipated expansion of Passage directly elevates investor willingness to pay premium valuations. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Passage Bio demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Investors evaluate Passage Bio using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Passage Bio's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. External factors like market trends, sector rotation, and investor psychology can cause Passage Bio's market price to deviate significantly from intrinsic value.
It's important to distinguish between Passage Bio's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Passage Bio should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Passage Bio's market price signifies the transaction level at which participants voluntarily complete trades.